Features of Pathobiology and Clinical Translation of Approved Treatments for Coronavirus Disease 2019.

IF 3.2 4区医学 Q3 VIROLOGY

Intervirology Pub Date : 2022-01-01 Epub Date: 2021-10-25 DOI:10.1159/000520234

Ali Fallah, Hadi Razavi Nikoo, Hamidreza Abbasi, Azadeh Mohammad-Hasani, Abasalt Hosseinzadeh Colagar, Ayyoob Khosravi

{"title":"Features of Pathobiology and Clinical Translation of Approved Treatments for Coronavirus Disease 2019.","authors":"Ali Fallah, Hadi Razavi Nikoo, Hamidreza Abbasi, Azadeh Mohammad-Hasani, Abasalt Hosseinzadeh Colagar, Ayyoob Khosravi","doi":"10.1159/000520234","DOIUrl":null,"url":null,"abstract":"Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently the most important etiological agent of acute respiratory distress syndrome (ARDS) with millions of infections and deaths in the last 2 years worldwide. Several reasons and parameters are responsible for the difficult management of coronavirus disease-2019 (COVID-19) patients; the first is virus behavioral factors such as high transmission rate, and the different molecular and cellular mechanisms of pathogenesis remain a matter of controversy, which is another factor.Summary: In the present review, we attempted to explain about features of SARS-COV-2, particularly focusing on the various aspects of pathogenesis and treatment strategies.Key messages: We note evidence for the understanding of the precise molecular and cellular mechanisms of SARS-CoV-2 pathogenesis, which can help design the appropriate drug or vaccine. Additionally, and importantly, we reported the updated issues associated with the history and development of treatment strategies such as, drugs, vaccines, and other medications that have been approved or under consideration in clinics and markets worldwide.","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805078/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intervirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000520234","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently the most important etiological agent of acute respiratory distress syndrome (ARDS) with millions of infections and deaths in the last 2 years worldwide. Several reasons and parameters are responsible for the difficult management of coronavirus disease-2019 (COVID-19) patients; the first is virus behavioral factors such as high transmission rate, and the different molecular and cellular mechanisms of pathogenesis remain a matter of controversy, which is another factor.

Summary: In the present review, we attempted to explain about features of SARS-COV-2, particularly focusing on the various aspects of pathogenesis and treatment strategies.

Key messages: We note evidence for the understanding of the precise molecular and cellular mechanisms of SARS-CoV-2 pathogenesis, which can help design the appropriate drug or vaccine. Additionally, and importantly, we reported the updated issues associated with the history and development of treatment strategies such as, drugs, vaccines, and other medications that have been approved or under consideration in clinics and markets worldwide.

Abstract Image

查看原文本刊更多论文

2019 年冠状病毒疾病病理生物学特征和获批疗法的临床转化。

背景：严重急性呼吸系统综合征冠状病毒-2（SARS-CoV-2）是目前导致急性呼吸窘迫综合征（ARDS）的最重要病原体，近两年来全球已有数百万人感染并死亡。造成冠状病毒病-2019（COVID-19）患者管理困难的原因和参数有几个；首先是病毒行为因素，如高传播率，而不同的分子和细胞发病机制仍存在争议，这是另一个因素。摘要：在本综述中，我们试图解释 SARS-COV-2 的特征，尤其侧重于发病机制和治疗策略的各个方面：我们注意到，有证据表明人们已经了解了 SARS-CoV-2 发病的确切分子和细胞机制，这有助于设计适当的药物或疫苗。此外，重要的是，我们还报告了与治疗策略的历史和发展相关的最新问题，如药物、疫苗和其他药物，这些药物已在世界各地的诊所和市场获得批准或正在考虑之中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Intervirology 医学-病毒学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Intervirology'' covers progress in both basic and clinical virus research, and aims to provide a forum for the various disciplines within virology. Issues publishing original papers alternate with thematic issues, focusing on clearly defined topics. This thematic concentration serves to make timely reviews, research reports and controversy easily accessible to both specialists in the field and those who want to keep track of the latest developments outside their own area of interest. In addition to original papers, regular issues publish short communications and letters to the editor to provide readers with a forum for the exchange of ideas and comments. The scope encompasses work on the molecular biology of human and animal viruses, including genome organization and regulation, and the structure and function of viral proteins. The pathogenesis, immunology, diagnosis, epidemiology, prophylaxis and therapy of viral diseases are considered.